Use of Vedolizumab in Inflammatory Bowel Disease: A Single-Center Experience
CONCLUSION: Vedolizumab therapy is effective in both induction and maintenance of remission in inflammatory bowel disease patients who are resistant to anti-tumor necrosis factor or who can not receive anti-tumor necrosis factor therapy due to side effects. No signifi- cant side effect was observed in the patients during follow-up.PMID:35946879 | DOI:10.5152/tjg.2022.21684
Source: The Turkish Journal of Gastroenterology - Category: Gastroenterology Authors: Çağdaş Erdoğan Bayram Ye şil Ferhat Bacaks ız Derya Ar ı Volkan G ökbulut Mahmut Y üksel Yasemin Özderin Özin Ertu ğrul Kayaçetin Source Type: research
More News: Crohn's Disease | Gastroenterology | Inflammatory Bowel Disease | Study | Turkey Health | Ulcerative Colitis